

28 February 2013

The Companies Announcements Office
The Australian Stock Exchange Limited
Sydney NSW

Appendix 4D – Half Year Report

1. Name of Entity **Bioxyne Limited**
ABN 97 084 464 193

Half year ended 31 December 2012

Reporting period 1 July 2012 to 31 December 2012

Previous period 1 July 2011 to 31 December 2011

2. Results for announcement to the market

	31 December 2012	31 December 2011	% Change
2.1 Revenues from continuing operations	398,926	Nil	N/M
2.2 Profit (loss) from continuing operations after tax attributable to members	(1,045,029)	(3,155,985)	66.89%
2.3 Net profit (loss) attributable to members	(1,045,029)	(3,155,985)	66.89%
2.4 Proposed dividends	Nil	Nil	N/M
2.5 Not applicable			

2.6 Under the accounting standard applicable to business acquisitions, *AASB 3 Business Combinations*, the acquisition of Hunter Immunology Limited ("HIL") by BXN on 3 April 2012 is required to be accounted for as a reverse acquisition of BXN by HIL. Under this scenario, HIL is deemed be the acquirer and BXN is deemed to be the subsidiary. Applying the reverse acquisition method of accounting, following the acquisition, the Consolidated Statement of Cash Flows is required to represent the continuation of the financial statements of HIL and its controlled entities.

As a result of the reverse acquisition methodology as outlined above, the lodged Consolidated Financial Statements and above comparative data represent the activities of HIL and its controlled entities from the date of acquisition.

It follows that the comparative figures for 31 December 2011 have been restated and differ from the 31 December 2011 figures lodged in the equivalent Appendix 4D in the prior year. The legal parent, Bioxyne Limited, had 'Revenues from continuing operations' of \$184,823 in its prior year lodgement and a 'Net (loss) from continuing operations/attributable to members' of (\$314,633) for the financial period to 31 December 2011.

- | | | | |
|----|---|-----------|-----------|
| 3. | Net tangible asset (liability) per security | 3.1 cents | 3.8 cents |
|----|---|-----------|-----------|

4. The company did not gain or lose control over any other entity during the reporting period.

As noted above however there was a gain of control event on 3 April 2012 which occurred between half year reporting periods. Therefore the numbers in this Appendix 4D should be read in accordance with section 2.6 of this lodgement.

5. There were no payments of dividends during the reporting period.
6. There is no dividend reinvestment plan in operation.
7. There are no associates or joint venture entities.
8. The company is not a foreign entity.
9. The accounts are not subject to any audit dispute or qualification.

The company's half year report follows.

Yours sincerely,

Jarrold T White
Company Secretary
28 February 2013



ABN: 97 084 464 193

Suite 404, Level 4
25 Lime Street
Sydney NSW 2072

P: +61 2 9844 5422
F: +61 2 9844 5445



BIOXYNE LIMITED

ABN 97 084 464 193

**Consolidated Interim Financial Report
For the Half-Year ended 31 December 2012**



Index

	Page
Corporate Information	2
Directors' Report	4
Auditor's Independence Declaration	5
Statement of Profit or Loss and Other Comprehensive Income	6
Statement of Financial Position	7
Statement of Changes in Equity	8
Statement of Cash Flows	9
Notes to the Financial Statements	10
Directors' Declaration	16
Independent Auditor's Report to the Members	17



**Bioxyne Limited Half-Year Report
31 December 2012**

Corporate Information

This half-year report covers Bioxyne Limited (the Company). The Company's functional and presentation currency is AUD.

A description of the Company's operation and of its principal activities is included in the review of operations and activities in the Directors' report on page 4. The Directors' report has not been reviewed by the Company's auditors and does not form part of the financial report.

Directors

Mr A. P Ho
Mr P. D Ford
Mr J. C Cook

Company Secretaries

Ms L. E Raymer
Mr J. T White

Auditors

RSM Bird Cameron Partners
Level 12, 60 Castlereagh Street,
SYDNEY NSW 2000

Bankers

National Australia Bank Limited

Share Register

Computershare Financial Services Pty Limited
Level 12, 565 Bourke Street,
MELBOURNE VIC 3001

Principal Solicitors

Addisons Lawyers
Level 12, 60 Carrington Street
Sydney, NSW 2000

Internet Address

www.bioxyne.com



Directors' Report

Your directors present their report of Bioxyne Limited (ASX: BXN) and its wholly owned subsidiary (the "Group") for the half -year ended 31 December 2012.

Directors

The following persons were directors of Bioxyne Limited during the half year and up to the date of this report:

David Radford	CEO and Managing Director (Resigned 12 December 2012)
Ian Mutton	Non-executive chairman (Resigned 29 November 2012)
Doug Wilson	Non-executive director (Resigned 26 October 2012)
Glenn Crisp	Non-executive director (Retired 30 October 2012)
William Harrison	Non-executive director (Retired 30 October 2012)
Patrick Douglas Ford	Non-executive director
Anthony Ho	Non-executive chairman (Appointed 30 October 2012)
Jeremy Curnock Cook	Non-executive director (Appointed 7 May 2012, retired 30 October 2012, appointed 12 December 2012)

Chief Executive Officer

Dr Phillip Comans was appointed as the Chief Executive Officer (CEO) of the Company on 12 December 2012 following the resignation of the former CEO.

Company Secretary

Ms Laura Raymer
Mr Jarrod White

Review of operations

During the period to 31 December 2012, the Company gained access to the full data set from the H-005 clinical trial, which enabled a detailed review and investigation of the data. This review is crucial in the planning of the way ahead for the Company's HI-164 project.

Following the November annual general meeting, the Board was reduced in size and reconstituted with the appointment of new chairman, Tony Ho and the re-joining to the Board of Jeremy Curnock Cook, together with director Patrick Ford. Dr Phillip Comans replaced David Radford as CEO.

Management and operating processes of the Company were also simplified to reduce costs.



Events Occurring After the Balance Sheet Date

Events occurring subsequent to balance date include:

- On 18 February, 2013 the Company announced to the ASX of the acquisition of sales and distribution business Vitality Devices Pty Limited, a marketing distributor of high value medical devices in Australia and other key South East Asia regions. Initial products focus on Chronic Heart Failure and Type 2 Diabetes;
- Initial products are already CE marked and have received reimbursement approvals in key markets including Germany and the USA. In addition, the "DIAMOND" diabetes device has received Australia's TGA approval;
- Capital injection and support from major shareholder, Phillip Asset Management Limited (PAM), of up to \$2.5 million as part of a proposed prospectus public offer to raise up to \$4 million.

The proposed acquisition of VITALITY and PAM's funding commitments are subject to a number of conditions precedents including:

- approvals of the board of directors of BXN, VITALITY and PAM;
- approvals of the shareholders of BXN and VITALITY;
- satisfactory due diligence;
- regulatory approvals; and
- mutually acceptable sale and subscription agreements.

On 20 February 2013, the Company announced to the ASX of the completion of a placement of shares to raised \$508,371 to provide working capital and to fund the transaction costs of the proposed acquisition.

A notice of meeting is intended to be dispatched to shareholders around the end of March for a shareholders meeting to be convened around the end of April 2013 to approve the proposed acquisition.

Auditor's Independence Declaration

The auditor's independence declaration is included on page 5 of the half-year report.

Signed in accordance with a resolution of directors made pursuant to s.306 (3) of the Corporations Act 2001.

On behalf of the Directors,

A handwritten signature in black ink, appearing to read "Anthony Ho".

**Anthony Ho,
Chairman**

RSM Bird Cameron Partners
Level 12, 60 Castlereagh Street Sydney NSW 2000
GPO Box 5138 Sydney NSW 2001
T +61 2 9233 8933 F +61 2 9233 8521

AUDITOR'S INDEPENDENCE DECLARATION

As lead auditor for the review of the financial report of Bioxyne Limited for the half year ended 31 December 2012, I declare that, to the best of my knowledge and belief, there have been no contraventions of:

- (i) the auditor independence requirements of the *Corporations Act 2001* in relation to the review; and
- (ii) any applicable code of professional conduct in relation to the review.

RSM Bird Cameron Partners

RSM BIRD CAMERON PARTNERS



G N SHERWOOD
Partner

Sydney, NSW
Dated: 27 February 2013



Bioxyne Limited

**Consolidated Statement of Profit or Loss and Other Comprehensive Income
For the Half-Year ended 31 December 2012**

	31 December 2012	31 December 2011
	\$	\$
Revenue from continuing operations		
Sale of goods	398,926	-
Other income	2,168	8,627
Cost of goods sold	(194,136)	-
Expenses		
Research and development	(406,850)	(1,263,821)
Business development	(32,885)	(731,378)
Marketing	(17,362)	(47,301)
General and administration	(1,283,140)	(827,049)
Finance costs	(31,205)	(346,511)
Loss before income tax	(1,564,484)	(3,207,433)
Income tax benefit	519,455	51,448
Other comprehensive income for the period, net of income tax	-	-
Total comprehensive loss for the period	(1,045,029)	(3,155,985)
Loss attributable to:		
Members of Bioxyne Limited	(1,045,029)	(3,155,985)
Earnings per share		
<i>From continuing operations</i>		
- Basic/diluted (loss)/earnings per share	(0.01)	(0.02)

The above Consolidated Statement of Profit or Loss and Other Comprehensive Income should be read in conjunction with the accompanying notes.



Bioxyne Limited
Consolidated Statement of Financial Position
As at 31 December 2012

	31 December 2012 \$	30 June 2012 \$
ASSETS		
Current Assets		
Cash and cash equivalents	507,939	779,624
Current tax receivables	-	1,529,528
Trade and other receivables	268,216	162,928
Total Current Assets	776,155	2,472,080
Non-Current Assets		
Deposit	-	200,000
Property plant and equipment	2,742	3,308
Deferred tax asset	4,754,156	4,234,701
Total Non-Current Assets	4,756,898	4,438,009
Total Assets	5,533,053	6,910,089
LIABILITIES		
Current Liabilities		
Trade and other payables	755,199	1,022,206
Total Current Liabilities	755,199	1,022,206
Total Liabilities	755,199	1,022,206
Net Assets	4,777,854	5,887,883
EQUITY		
Contributed equity	27,969,432	28,034,432
Reserves	654,145	750,977
Accumulated losses	(23,845,723)	(22,897,526)
Total Equity	4,777,854	5,887,883

The above Consolidated Statement of Financial Position should be read in conjunction with the accompanying notes.



Bioxyne Limited
Consolidated Statement of Changes in Equity
For the Half-Year ended 31 December 2012

	Contributed equity \$	Accumulated Losses \$	Reserves \$	Total \$
2011				
At 1 July 2011	16,767,001	(21,113,396)	654,146	(3,692,249)
Loss after income tax for the half year	-	(3,155,985)	-	(3,155,985)
Other comprehensive income for the half year	-	-	-	-
Total comprehensive income for the half year	-	(3,155,985)	-	(3,155,985)
Contributions of equity, net of transaction costs	165,634	-	-	165,634
As at 31 December 2011	16,932,635	(24,269,381)	654,146	6,682,600
2012				
At 1 July 2012	28,034,432	(22,897,526)	750,977	5,887,883
Loss after income tax for the half year	-	(1,045,029)	-	(1,045,029)
Other comprehensive income for the half year	-	-	-	-
Total comprehensive income for the half year	-	(1,045,029)	-	(1,045,029)
Contributions of equity, net of transaction costs	(65,000)	-	-	(65,000)
Options cancelled during the period		96,832	(96,832)	-
As at 31 December 2012	27,969,432	(23,845,723)	654,145	4,777,854

The above Consolidated Statement of Changes in Equity should be read in conjunction with the accompanying notes



Bioxyne Limited
Consolidated Statement of Cash Flows
For the Half-Year ended 31 December 2012

	31 December 2012 \$	31 December 2011 \$
Cash flows from operating activities		
Receipts of other income (inclusive of goods and services tax)	273,781	-
Payments to suppliers and employees (inclusive of goods and services tax)	(1,980,753)	(2,763,890)
	(1,706,972)	(2,763,890)
Research and development tax rebate	1,529,528	909,534
Finance charges	(31,205)	(456)
Interest received	1,964	8,627
Net cash outflow from operating activities	(206,685)	(1,846,185)
Cash flows from investing activities		
Acquisition of property plant and equipment	-	(2,054)
Net cash outflow from investing activities	-	(2,054)
Cash flows from financing activities		
Proceeds from issues of shares net of transaction costs	-	382,686
Proceeds from convertible note	-	3,000,000
Costs of raising equity	(65,000)	-
Net cash (outflow) inflow from financing activities	(65,000)	3,382,686
Net (decrease) increase in cash and cash equivalents	(271,685)	1,534,447
Cash and cash equivalents at the beginning of the financial period	779,624	705,692
Cash and cash equivalents at end of the period	507,939	2,240,139

The above Consolidated Statement of Cash Flows should be read in conjunction with the accompanying notes.



Bioxyne Limited
Notes to the Financial Statements
For the Half-Year ended 31 December 2012

1 Summary of significant accounting policies

(a) Basis of preparation

These general purpose financial statements for the interim half year reporting period ended 31 December 2012 have been prepared in accordance with the requirements of the Corporations Act 2001 and Australian Accounting Standard AASB 134 *Interim Financial Reporting*. Compliance with Australian Accounting Standards ensures that the financial statements and notes comply with International Financial Reporting Standards.

The interim financial report is intended to provide users with an update on the latest annual financial statements of Bioxyne Limited and its controlled entity. As such, it does not contain the information that represents relatively insignificant changes occurring during the half-year within the consolidated entity. It is recommended that this financial report be read in conjunction with the annual financial statements of the consolidated entity for the year ended 30 June 2012 together with any public announcements made during the half year.

The same accounting policies and methods of computation have been followed in this interim financial report as were applied in the most recent annual financial statements.

(b) Going concern

The financial statements have been prepared on the going concern basis, which contemplates continuity of normal business activities and the realisation of assets and discharge of liabilities in the normal course of business.

While the Group has experienced recurring operating losses and negative cash flows from operations during the half year ended 31 December 2012 of \$1,045,029 and \$206,685 respectively, this is typical of early stage drug development companies.

The Directors believe that it is reasonably foreseeable that the consolidated group will continue as a going concern and that it is appropriate to adopt the going concern basis in the preparation of the financial report after consideration of the following factors:

- (a) The Company has recently announced an expansion of its sales and distribution business with the proposed acquisition of Vitality Devices Pty Limited with the support of Phillip Asset Management Limited (PAM), a major shareholder, see note 4. Capital injections and support from PAM, of up to \$2.5 million is expected as part of a proposed prospectus public offer to raise up to \$4 million. The expected funding would enable the Company to be properly funded for its operations for the foreseeable future.
- (b) On 20 February 2013, the Company announced to the ASX the completion of a placement of shares to raise \$508,371 to provide working capital and to fund the transaction costs of the proposed acquisition.
- (c) The ability of the consolidated group to undertake further capital raisings to provide the required funding to meet the consolidated group's ongoing operating costs and / or
- (d) The ability to enter into negotiations with a potential partner to commercialise the consolidated group's intellectual property.



Bioxyne Limited
Notes to the Financial Statements
For the Half-Year ended 31 December 2012

1 Summary of significant accounting policies (continued)

(c) Critical accounting estimates and judgments

The critical accounting estimates and judgments are consistent with those applied and disclosed in the June 2012 annual report.

(d) New and revised accounting requirements applicable to the current half- year reporting period.

New and revised Standards and amendments thereof and Interpretations effective for the current half-year that are relevant to the Group include; amendments to AASB 1, 5, 7, 101, 112, 120, 121, 132, 133 and 134 as a consequence of AASB 2011-9 'Amendments to Australian Accounting Standards – Presentation of Items of Other Comprehensive Income'

The adoption of all the new and revised Standards and Interpretations has not resulted in any changes to the Group's accounting policies and has no effect on the amounts reported for the current or prior half-years. However, the application of AASB 2011-9 has resulted in changes to the Group's presentation of, or disclosure in, its half-year financial statements.

AASB 2011-9 introduces new terminology for the statement of comprehensive income and income statement. Under the amendments to AASB 101, the statement of comprehensive income is renamed as a statement of profit or loss and other comprehensive income and the income statement is renamed as a statement of profit or loss. The amendments to AASB 101 retain the option to present profit or loss and other comprehensive income in either a single statement or in two separate but consecutive statements. However, the amendments to AASB 101 require items of other comprehensive income to be grouped into two categories in the other comprehensive income section: (a) items that will not be reclassified subsequently to profit or loss and (b) items that may be reclassified subsequently to profit or loss when specific conditions are met. Income tax on items of other comprehensive income is required to be allocated on the same basis – the amendments do not change the option to present items of other comprehensive income either before tax or net of tax. The amendments have been applied retrospectively, and hence the presentation of items of other comprehensive income has been modified to reflect the changes. Other than the above mentioned presentation changes, the application of the amendments to AASB 101 does not result in any impact on profit or loss, other comprehensive income and total comprehensive income.



Bioxyne Limited
Notes to the Financial Statements
For the Half-Year ended 31 December 2012

2 Segment information

Bioxyne operates in the bio-technology industry in Australia. The principal operations are to research, develop, market and distribute over the counter pharmaceutical products. Sales are made both in Australia and internationally.

Hunter immunology also operates in the bio-technology industry in Australia. Its current principal operations are to research and develop immunotherapeutics. On successful development of such products, Hunter Immunology will seek to commercialise the product.

The following table presents revenue and profit information and certain asset and liability information regarding geographical segments for the half year ended 31 December 2012 and 31 December 2011.

Segment revenues and results

	Segment revenue		Segment profit	
	31 December	31 December	31 December	31 December
	2012	2011	2012	2011
	\$	\$	\$	\$
Over the counter pharmaceutical	398,926	-	197,155	-
Immunotherapeutics	-	-	(432,100)	(1,995,199)
Other	2,168	8,627	2,168	8,627
Total for continuing operations	401,094	8,627	(232,777)	(1,986,572)
Central administration costs and directors salaries			(1,300,502)	(874,350)
Finance costs			(31,205)	(346,511)
(Loss) before tax (continuing operations)			(1,564,484)	(3,207,433)

Segment revenue reported above represents revenue generated from external customers. There were no inter-segment sales in the current period (2011: Nil).

The accounting policies of the reportable segments are the same as the Group's accounting policies described in note 1. Segment profit represents the profit earned by each segment without allocation of central administration costs and directors' salaries, share of profits of associates, gain recognised on disposal of interest in former associate, investment income, gains and losses, finance costs and income tax expense. This is the measure reported to the chief operating decision maker for the purposes of resource allocation and assessment of segment performance.



Bioxyne Limited
Notes to the Financial Statements
For the Half-Year ended 31 December 2012

2 Segment Information (Continued)

Segment assets

	31 December 2012	30 June 2012
	\$	\$
Over the counter pharmaceutical Immunotherapeutics	436,972 5,096,081	624,121 6,285,968
Total segment assets	5,533,053	6,910,089
Unallocated	-	-
Consolidated total assets	5,553,053	6,910,089

Segment liabilities

Over the counter pharmaceutical Immunotherapeutics	220,312 534,887	200,867 821,339
Total segment liabilities	755,199	1,022,206
Unallocated	-	-
Consolidated total liabilities	755,199	1,022,206

For the purposes of monitoring segment performance and allocating resources between segments:

- All assets are allocated to reportable segments other than interests in associates, 'other financial assets' and current and deferred tax assets. Goodwill is allocated to reportable segments;
- Assets used jointly by reportable segments are allocated on the basis of the revenues earned by individual reportable segments; and
- All liabilities are allocated to reportable segments other than borrowings, 'other financial, liabilities', current and deferred tax liabilities. Liabilities for which reportable segments are jointly liable are allocated in proportion to segment assets.



Bioxyne Limited
Notes to the Financial Statements
For the Half-Year ended 31 December 2012

2 Segment Information (Continued)

Geographical information

	Australia		USA		Europe		Total	
	Dec 2012	Dec 2011	Dec 2012	Dec 2011	Dec 2012	Dec 2011	Dec 2012	Dec 2011
Revenue								
External sales	-	-	398,926	-	-	-	398,926	-
Other revenues from external customers	2,168	8,627	-	-	-	-	2,168	8,627
Segment revenue	2,168	8,627	398,926	-	-	-	401,094	8,627

Assets and liabilities

	Dec 2012	Jun 2012	Dec 2012	Jun 2012	Dec 2012	Jun 2012	Dec 2012	Jun 2012
Segment assets	5,533,053	6,910,089	-	-	-	-	5,533,053	6,910,089
Segment liabilities	755,199	1,022,206	-	-	-	-	755,199	1,022,206

3 Commitments

There were no commitments as at 31 December 2012.

4 Events Occurring After the Balance Sheet Date

Events occurring subsequent to balance date include:

- On 18 February, 2013 the Company announced to the ASX of the acquisition of sales and distribution business Vitality Devisces Pty Limited, a marketing distributor of high value medical devices in Australia and other key South East Asia regions. Initial products focus on Chronic Heart Failure and Type 2 Diabetes;
- Initial products are already CE marked and have received reimbursement approvals in key markets including Germany and the USA. In addition, the "DIAMOND" diabetes device has received Australia's TGA approval;
- Capital injection and support from major shareholder, Phillip Asset Management Limited (PAM), of up to \$2.5 million as part of a proposed prospectus public offer to raise up to \$4 million.



Bioxyne Limited
Notes to the Financial Statements
For the Half-Year ended 31 December 2012

4 Events Occurring After the Balance Sheet Date (Continued)

The proposed acquisition of VITALITY and PAM's funding commitments are subject to a number of conditions precedents including:

- approvals of the board of directors of BXN, VITALITY and PAM;
- approvals of the shareholders of BXN and VITALITY;
- satisfactory due diligence;
- regulatory approvals; and
- mutually acceptable sale and subscription agreements.

On 20 February 2013, the Company announced to the ASX of the completion of a placement of shares to raised \$508,371 to provide working capital and to fund the transaction costs of the proposed acquiairion.

A notice of meeting is intended to be dispatched to shareholders around the end of March for a shareholders meeting to be convened around the end of April 2013 to approve the proposed acquisition



Bioxyne Limited
Directors Declaration
For the Half-Year ended 31 December 2012

Declaration by Directors

The directors of the company declare that:

1. The financial statements and notes, as set out on pages 6 to 15, are in accordance with the Corporations Act 2001 including:
 - (a) compliance with Accounting Standard *AASB 134 Interim Financial Reporting*; and
 - (b) giving a true and fair view of the company's financial position as at 31 December 2012 and of its performance for the half year ended on that date.
2. In the directors' opinion, there are reasonable grounds to believe that the company will be able to pay its debts as and when they become due and payable.

This declaration is made in accordance with a resolution of the Board of Directors and is signed for and on behalf of the directors by:

A handwritten signature in dark ink, appearing to read "Anthony Ho".

Anthony Ho

Chairman

INDEPENDENT AUDITOR'S REVIEW REPORT
TO THE MEMBERS OF
BIOXYNE LIMITED

Report on the Half-Year Financial Report

We have reviewed the accompanying half-year financial report of Bioxyne Limited which comprises the condensed statement of financial position as at 31 December 2012, the condensed statement of comprehensive income, condensed statement of changes in equity and condensed statement of cash flows for the half-year ended on that date, notes comprising a summary of significant accounting policies and other explanatory information, and the directors' declaration of the consolidated entity comprising the company and the entity it controlled at the half-year end or from time to time during the half-year.

Directors' Responsibility for the Half-Year Financial Report

The directors of the company are responsible for the preparation of the half-year financial report that gives a true and fair view in accordance with Australian Accounting Standards and the *Corporations Act 2001* and for such internal control as the directors determine is necessary to enable the preparation of the half-year financial report that is free from material misstatement, whether due to fraud or error.

Auditor's Responsibility

Our responsibility is to express a conclusion on the half-year financial report based on our review. We conducted our review in accordance with Auditing Standard on Review Engagements ASRE 2410 *Review of a Financial Report Performed by the Independent Auditor of the Entity*, in order to state whether, on the basis of the procedures described, we have become aware of any matter that makes us believe that the half-year financial report is not in accordance with the *Corporations Act 2001* including: giving a true and fair view of the company's financial position as at 31 December 2012 and its performance for the half-year ended on that date; and complying with Accounting Standard AASB 134 *Interim Financial Reporting* and the *Corporations Regulations 2001*. As the auditor of Bioxyne Limited, ASRE 2410 requires that we comply with the ethical requirements relevant to the audit of the annual financial report.

A review of a half-year financial report consists of making enquiries, primarily of persons responsible for financial and accounting matters, and applying analytical and other review procedures. A review is substantially less in scope than an audit conducted in accordance with Australian Auditing Standards and consequently does not enable us to obtain assurance that we would become aware of all significant matters that might be identified in an audit. Accordingly, we do not express an audit opinion.

Independence

In conducting our review, we have complied with the independence requirements of the *Corporations Act 2001*. We confirm that the independence declaration required by the *Corporations Act 2001*, which has been given to the directors of Bioxyne Limited, would be in the same terms if given to the directors as at the time of this auditor's report.

Conclusion

Based on our review, which is not an audit, we have not become aware of any matter that makes us believe that the half-year financial report of Bioxyne Limited is not in accordance with the *Corporations Act 2001* including:

- (a) giving a true and fair view of the consolidated entity's financial position as at 31 December 2012 and of its performance for the half-year ended on that date; and
- (b) complying with Accounting Standard AASB 134 *Interim Financial Reporting* and *Corporations Regulations 2001*.

RSM Bird Cameron Partners

RSM BIRD CAMERON PARTNERS


G N SHERWOOD
Partner

Sydney, NSW
Dated: 28 February 2013